Plasminogen

Ryplazim™ (plasminogen) is the first biopharmaceutical expected to be launched commercially pending the review and approval of the BLA (Biologic License Application) submitted to the FDA for the treatment of congenital plasminogen deficiency.

  • Prometic announces second annual plasminogen deficiency awareness week

    Prometic announces second annual plasminogen deficiency awareness week

    This initiative, sponsored by Prometic, aims to raise awareness and improve understanding of this rare disease and its effects. Plasminogen Deficiency Awareness Week is a free 4-day online event

    Read Article
  • Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA

    Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA

    Implementation plan for additional analytical assays and in-process controls confirmed and PLI finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing

    Read Article
  • Prometic reports second quarter 2018 financial results and highlights

    Prometic reports second quarter 2018 financial results and highlights

    Prometic has advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).

    Read Article
  • Prometic reports its Q4-2017 and annual 2017 financial results and provides update on activities

    Prometic reports its Q4-2017 and annual 2017 financial results and provides update on activities

    Lead drug candidates PBI-4050 and Ryplazim™ (plasminogen) continue to deliver consistent and positive clinical activity and tolerability data

    Read Article
  • Prometic announces realignment of its clinical program priorities for 2018

    Prometic announces realignment of its clinical program priorities for 2018

    RyplazimTM (plasminogen) is the first biopharmaceutical expected to be launched commercially pending the review of its BLA

    Read Article
  • Prometic’s Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF)

    Prometic’s Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF)

    In a gold-standard animal model proven to emulate pulmonary fibrosis in humans, Prometic’s Plasminogen (Ryplazim™) performed favorably compared to recently- approved IPF drugs to treat this condition.

    Read Article
  • Prometic enters into binding letter of intent to secure USD $80 million (CAD $100 million) line of credit from structured Alpha LP

    Prometic enters into binding letter of intent to secure USD $80 million (CAD $100 million) line of credit from structured Alpha LP

    The transaction will bridge expected plasminogen (RyplazimTM) revenues as well as other asset monetization events.

    Read Article
  • Find out more about Plasminogen Deficiency (PLGD)

    Learn More
  • Prometic reports third quarter 2016 highlights and financial results

    Prometic reports third quarter 2016 highlights and financial results

    Plasminogen pivotal clinical trial results performed at 100% response rate meeting primary and secondary end points in plasminogen deficient patients

    Read Article
  • Pivotal data for Prometic’s intravenous Plasminogen replacement therapy to be presented at American Society for Hematology

    Pivotal data for Prometic’s intravenous Plasminogen replacement therapy to be presented at American Society for Hematology

    Prometic today announced that it will have two presentations at the 59th American Society of Hematology (ASH) Annual Meeting being held Dec. 9-12, 2017 in Atlanta.

    Read Article
  • Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer phase 2 clinical trial

    Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer phase 2 clinical trial

    The Phase 2 clinical trial is a prospective, dose escalation study of the safety, feasibility and initial efficacy of subcutaneous plasminogen for the treatment of DFU in 20 adult subjects.

    Read Article
  • Prometic receives priority review status from Health Canada for Plasminogen (Ryplazim™)

    Prometic receives priority review status from Health Canada for Plasminogen (Ryplazim™)

    Read Article
  • Prometic announces FDA acceptance of its biologics license application for Plasminogen (Ryplazim™)

    Prometic announces FDA acceptance of its biologics license application for Plasminogen (Ryplazim™)

    The acceptance of our BLA filing and setting of the PDUFA date by the FDA is a significant milestone for Prometic”, said Mr. Pierre Laurin, President and Chief Executive Officer of Prometic.

    Read Article
  • Prometic receives rare pediatric disease designation from U.S. FDA for its Plasminogen replacement therapy

    Prometic receives rare pediatric disease designation from U.S. FDA for its Plasminogen replacement therapy

    Prometic today announced that the U.S Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to Prometic’s Ryplazim, a plasminogen replacement therapy.

    Read Article
  • Prometic announces positive long term clinical data on Ryplazim™ in Plasminogen congenital deficiency and provides regulatory update

    Prometic announces positive long term clinical data on Ryplazim™ in Plasminogen congenital deficiency and provides regulatory update

    Ryplazim™ (Plasminogen IV) long-term treatment shown to prevent recurrence of lesions at 48 weeks and maintains the same safety, tolerability profile without any serious adverse events at 48 weeks.

    Read Article
  • Prometic presents new data on PBI-4050 and Plasminogen at the American Thoracic Society’s 2017 international conference

    Prometic presents new data on PBI-4050 and Plasminogen at the American Thoracic Society’s 2017 international conference

    Prometic presented new data at the 2017 American Thoracic Society (ATS) International Conference in Washington, D.C.

    Read Article
  • Prometic to present new data on how plasminogen reduces acute lung injury at the American Thoracic Society’s 2017 international conference

    Prometic to present new data on how plasminogen reduces acute lung injury at the American Thoracic Society’s 2017 international conference

    Prometic announced today that it will be presenting new data at the 2017 American Thoracic Society International Conference in Washington, D.C.showing the benefits of plasminogen in lung injury.

    Read Article
  • Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency2:17

    Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency

    At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).

    Watch Video
  • Prometic completes the filing of its plasminogen biologics license application (“BLA”) with the U.S. FDA

    Prometic completes the filing of its plasminogen biologics license application (“BLA”) with the U.S. FDA

    The completion of the plasminogen BLA filing is a significant milestone achievement for Prometic and, eventually, for all the patients who suffer from the complications associated with this deficiency

    Read Article
  • PBI-4050 has been issued a Promising Innovative Medicine (“PIM”) by MHRA

    PBI-4050 has been issued a Promising Innovative Medicine (“PIM”) by MHRA

    PBI-4050 has been issued a Promising Innovative Medicine (“PIM”) designation by the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) for the treatment of Alström Syndrome (“AS”).

    Read Article
  • Prometic Reacquires Plasminogen Rights From Hematech

    Prometic Reacquires Plasminogen Rights From Hematech

    Prometic has reacquired the rights initially granted to Hematech in the License Agreement, to a 50% share of the worldwide profits related to plasminogen congenital deficiency sales

    Read Article
  • loading
    Loading More...